1
|
Zouré AA, Amegnona LJ, Zongo N, Kiendrebeogo IT, Sorgho PA, Zongo FI, Yonli AT, Sombié HK, Bambara AH, Sawadogo AY, Ouedraogo MNL, Traoré L, Zongo SV, Lallogo DT, Bazié BVJTE, Zohoncon TM, Dijgma FW, Simpore J. Carriage of HLA-DRB1*11 and 1*12 alleles and risk factors in patients with breast cancer in Burkina Faso. Open Life Sci 2021; 16:1101-1110. [PMID: 34712820 PMCID: PMC8511965 DOI: 10.1515/biol-2021-0113] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 07/28/2021] [Accepted: 08/16/2021] [Indexed: 01/20/2023] Open
Abstract
Several factors contribute to the development of breast cancer, including the immune system. This study is aimed to characterize the carriage of human leukocyte antigen (HLA)-DRB1*11 and 1*12 alleles in patients with breast cancer. This case-control study consisted of 96 histologically diagnosed breast cancer cases and 102 controls (cases without breast abnormalities). A multiplex polymerase chain reaction (PCR) was used to characterize the carriage of HLA-DRB1*11 and 1*12 alleles. The HLA-DRB1*11 allele was present in 26.59% of cases and 22.55% of controls. The HLA-DRB1*12 allele was present in 56.63% of cases and 55.88% of controls. This study found no direct association between the carriage of the HLA-DRB1*11 and HLA-DRB1*12 alleles and the occurrence of breast cancer. In addition, the deletion of the HLA-DRB1*11 allele is associated (beneficial effect) with obesity/overweight (OR = 0.13; 95% CI [0.01-1.14]; and p = 0.03) which is a risk for breast cancer. No direct association was found between the carriage of HLA-DRB1*11 and 1*12 alleles and breast cancer risk. However, further investigation of other HLA alleles involved in the occurrence of breast cancer may provide more information.
Collapse
Affiliation(s)
- Abdou Azaque Zouré
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
- Department of Biomedical and Public Health/Institute of Health Sciences Research, (IRSS/CNRST), Institute of Health Sciences Research, 03 BP 7192, Ouagadougou 03, Burkina Faso
| | - Lanyo Jospin Amegnona
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
| | - Nayi Zongo
- Department of Surgery and Surgical Specialties, Service of General and Digestive Surgery, University Hospital Centre-Yalgado OUEDRAOGO, UFR/SDS, University Joseph KI-ZERBO, 03 BP 7021, Ouagadougou 03, Burkina Faso
| | - Isabelle Touwendpoulimdé Kiendrebeogo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Pegdwendé Abel Sorgho
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Fabienne Ingrid Zongo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Albert Théophane Yonli
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Herman Karim Sombié
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Aboubacar Hierrhum Bambara
- Department of Medicine and Medical Specialties, Service of Oncology, University Hospital Centre-BOGODOGO, University Joseph KI-ZERBO, UFR/SDS, 03 BP 7021, Ouagadougou 03, Burkina Faso
| | - Alexis Yobi Sawadogo
- Department of Gynecology-Obstetrics, Service of Gynecology, University Hospital Centre-BOGODOGO, University Joseph KI ZERBO, UFR/SDS, 03 BP 7021, Ouagadougou 03, Burkina Faso
| | - Marie N. L. Ouedraogo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
- Faculty of Medicine, University Saint Thomas d’Aquin, 06 BP 10212, Ouagadougou 01, Burkina Faso
| | - Lassina Traoré
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Sidnooma Véronique Zongo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Doriane Tatiana Lallogo
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Bapio Valery Jean Télesphore Elvira Bazié
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Théodora M. Zohoncon
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
- Faculty of Medicine, University Saint Thomas d’Aquin, 06 BP 10212, Ouagadougou 01, Burkina Faso
| | - Florencia W. Dijgma
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Jacques Simpore
- Departement of Biochemistry and Microbiology, Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR/SVT, University Joseph KI-ZERBO, 03 P.O. Box 7021, Ouagadougou 03, Burkina Faso
- Departement of Molecular Biology, Pietro Annigoni Biomolecular Research Center (CERBA), 01 P.O. Box 364, Ouagadougou 01, Burkina Faso
| |
Collapse
|
2
|
Sarri CA, Giannoulis T, Moutou KA, Mamuris Z. HLA class II peptide-binding-region analysis reveals funneling of polymorphism in action. Immunol Lett 2021; 238:75-95. [PMID: 34329645 DOI: 10.1016/j.imlet.2021.07.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 07/05/2021] [Accepted: 07/17/2021] [Indexed: 01/24/2023]
Abstract
BACKGROUND HLA-class II proteins hold important roles in key physiological processes. The purpose of this study was to compile all class II alleles reported in human population and investigate patterns in pocket variants and their combinations, focusing on the peptide-binding region (PBR). METHODS For this purpose, all protein sequences of DPA1, DQA1, DPB1, DQB1 and DRB1 were selected and filtered, in order to have full PBR sequences. Proportional representation was used for pocket variants while population data were also used. RESULTS All pocket variants and PBR sequences were retrieved and analyzed based on the preference of amino acids and their properties in all pocket positions. The observed number of pocket variants combinations was much lower than the possible inferred, suggesting that PBR formation is under strict funneling. Also, although class II proteins are very polymorphic, in the majority of the reported alleles in all populations, a significantly less polymorphic pocket core was found. CONCLUSIONS Pocket variability of five HLA class II proteins was studied revealing favorable properties of each protein. The actual PBR sequences of HLA class II proteins appear to be governed by restrictions that lead to the establishment of only a fraction of the possible combinations and the polymorphism recorded is the result of intense funneling based on function.
Collapse
Affiliation(s)
- Constantina A Sarri
- Department of Biochemistry and Biotechnology, Laboratory of Genetics, Comparative and Evolutionary Biology, University of Thessaly, Viopolis, Mezourlo, 41500, Larisa, Greece
| | - Themistoklis Giannoulis
- Department of Biochemistry and Biotechnology, Laboratory of Genetics, Comparative and Evolutionary Biology, University of Thessaly, Viopolis, Mezourlo, 41500, Larisa, Greece; Department of Animal Science, University of Thessaly, Trikallon 224, 43100 Karditsa, Greece
| | - Katerina A Moutou
- Department of Biochemistry and Biotechnology, Laboratory of Genetics, Comparative and Evolutionary Biology, University of Thessaly, Viopolis, Mezourlo, 41500, Larisa, Greece
| | - Zissis Mamuris
- Department of Biochemistry and Biotechnology, Laboratory of Genetics, Comparative and Evolutionary Biology, University of Thessaly, Viopolis, Mezourlo, 41500, Larisa, Greece.
| |
Collapse
|
3
|
Liu L, Sun X, Yuan C, Liu H. Relationship between HLA-DRB1 gene polymorphism and breast cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e25078. [PMID: 33761666 PMCID: PMC9282000 DOI: 10.1097/md.0000000000025078] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Accepted: 02/16/2021] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Breast cancer is one of the common malignant tumors in women, which seriously affects women's physical and mental health and even life-threatening. The occurrence and development of breast cancer are closely related to genetic factors. Many studies have shown that human leukocyte antigen DRB1 is associated with the development of breast cancer, but lack evidence. This study aims to systematically evaluate the relationship between HLA-DRB1 gene polymorphism and breast cancer. METHODS The retrieval time of this study was from the establishment of the database to February 2021. The retrieval databases included CNKI, Wanfang, VIP and China Biomedical Database, PubMed, Embase, Web of Science, and the Cochrane Library. The retrieval objects were observational studies on the relationship between HLA-DRB1 gene polymorphism and breast cancer (including case--control studies, cross-sectional studies, and cohort studies). The language restrictions were English and Chinese. Two researchers independently extracted the data and assessed the quality of the included studies, and Stata 16.0 software was used for statistical analysis. RESULTS This study will systematically evaluate the relationship between HLA-DRB1 gene polymorphism and breast cancer based on existing studies. CONCLUSION This study will explore the early warning signal of breast cancer genetic susceptibility, and provide evidence-based medical evidence for clarifying the role of HLA-DRB1 gene polymorphism in breast cancer. OSF REGISTRATION NUMBER DOI 10.17605/OSF.IO/847FQ.
Collapse
Affiliation(s)
- Linlin Liu
- Department of Integrated TCM and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
| | - Xu Sun
- Department of Integrated TCM and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
| | - Chenxi Yuan
- Department of Integrated TCM and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
| | - Huaimin Liu
- Department of Integrated TCM and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
| |
Collapse
|
4
|
Rotimi SO, Rotimi OA, Salhia B. A Review of Cancer Genetics and Genomics Studies in Africa. Front Oncol 2021; 10:606400. [PMID: 33659210 PMCID: PMC7917259 DOI: 10.3389/fonc.2020.606400] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 12/14/2020] [Indexed: 12/24/2022] Open
Abstract
Cancer is the second leading cause of death globally and is projected to overtake infectious disease as the leading cause of mortality in Africa within the next two decades. Cancer is a group of genomic diseases that presents with intra- and inter-population unique phenotypes, with Black populations having the burden of morbidity and mortality for most types. At large, the prevention and treatment of cancers have been propelled by the understanding of the genetic make-up of the disease of mostly non-African populations. By the same token, there is a wide knowledge gap in understanding the underlying genetic causes of, and genomic alterations associated with, cancer among black Africans. Accordingly, we performed a review of the literature to survey existing studies on cancer genetics/genomics and curated findings pertaining to publications across multiple cancer types conducted on African populations. We used PubMed MeSH terms to retrieve the relevant publications from 1990 to December 2019. The metadata of these publications were extracted using R text mining packages: RISmed and Pubmed.mineR. The data showed that only 0.329% of cancer publications globally were on Africa, and only 0.016% were on cancer genetics/genomics from Africa. Although the most prevalent cancers in Africa are cancers of the breast, cervix, uterus, and prostate, publications representing breast, colorectal, liver, and blood cancers were the most frequent in our review. The most frequently reported cancer genes were BRCA1, BRCA2, and TP53. Next, the genes reported in the reviewed publications’ abstracts were extracted and annotated into three gene ontology classes. Genes in the cellular component class were mostly associated with cell part and organelle part, while those in biological process and molecular function classes were mainly associated with cell process, biological regulation, and binding, and catalytic activity, respectively. Overall, this review highlights the paucity of research on cancer genomics on African populations, identified gaps, and discussed the need for concerted efforts to encourage more research on cancer genomics in Africa.
Collapse
Affiliation(s)
- Solomon O Rotimi
- Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.,Department of Biochemistry, Covenant University, Ota, Nigeria
| | - Oluwakemi A Rotimi
- Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.,Department of Biochemistry, Covenant University, Ota, Nigeria
| | - Bodour Salhia
- Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.,Norris Comprehensive Cancer Centre, University of Southern California, Los Angeles, CA, United States
| |
Collapse
|
5
|
Aureli A, Canossi A, Del Beato T, Buonomo O, Rossi P, Roselli M, Papola F, Marziani B, Sconocchia G. Breast Cancer Is Associated with Increased HLA-DRB1*11:01 and HLA-DRB1*10:01 Allele Frequency in a Population of Patients from Central Italy. Immunol Invest 2020; 49:489-497. [PMID: 32183601 DOI: 10.1080/08820139.2020.1737539] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The relationship between HLA-DRB1 allele polymorphism and breast cancer (BC) development is still unclear and needs further investigation. To address this issue, we analyzed HLA-DRB1 allele frequency (AF) by sequence-based typing (SBT) in 47 patients from central Italy with BC and 156 sex and age-matched healthy controls. Two hundred ninety-seven individuals from the same region were utilized as historical controls. Pearson's chi-square analysis with Yate's correction or Fisher's Exact test with Bonferroni's correction, as appropriate, were used to compare HLA-DRB1 AF differences in patients and controls. A total of 36 HLA-DRB1 alleles were identified. A detailed study showed that HLA-DRB1*11:01 and HLA-DRB1*10:01 alleles are significantly associated with increased BC risk. In particular, HLA-DRB1*11:01 AF was significantly higher in patients with BC than in healthy females and historical controls, even following Bonferroni's correction (stage I-II BC patients vs historical controls p<0.00; stage III-IV BC patients vs female healthy controls p=0.025 and historical controls p<0.00). The HLA-DRB1*10:01 allele was also positively associated with BC as evidenced by a significantly higher AF in patients with BC than in healthy controls (BC patients stage I-II vs historical controls corrected p =0.01). These results suggest that both HLA-DRB1*11:01 and HLA-DRB1*10:01 AF could represent interesting markers in patients at risk of developing BC.
Collapse
Affiliation(s)
- Anna Aureli
- Department of Biomedicine, CNR Institute of Translational Pharmacology , Rome and L'Aquila, Italy
| | - Angelica Canossi
- Department of Biomedicine, CNR Institute of Translational Pharmacology , Rome and L'Aquila, Italy
| | - Tiziana Del Beato
- Department of Biomedicine, CNR Institute of Translational Pharmacology , Rome and L'Aquila, Italy
| | - Oreste Buonomo
- Department of Experimental Medicine and Surgery, The University of Rome , Tor Vergata, Italy
| | - Piero Rossi
- Department of Experimental Medicine and Surgery, The University of Rome , Tor Vergata, Italy
| | - Mario Roselli
- Department of Systems Medicine, Endocrinology and Medical Oncology, University of Rome "Tor Vergata" , Rome, Italy
| | - Franco Papola
- Regional Center of Immunohematology and Tissue Typing, CRITT S. Salvatore Hospital , L'Aquila, Italy
| | - Beatrice Marziani
- Department of Experimental Medicine and Surgery, The University of Rome , Tor Vergata, Italy
| | - Giuseppe Sconocchia
- Department of Biomedicine, CNR Institute of Translational Pharmacology , Rome and L'Aquila, Italy
| |
Collapse
|
6
|
Vahedi SM, Nikbakht G, Jamshidi S, Lankarani L, Alimi N, Esmailnejad A. Association between DLA-DRB1.2 allelic diversity and development of mammary gland tumors in dogs. Acta Vet Scand 2019; 61:55. [PMID: 31727096 PMCID: PMC6857217 DOI: 10.1186/s13028-019-0491-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Accepted: 11/04/2019] [Indexed: 01/12/2023] Open
Abstract
Background The major histocompatibility complex (MHC) is the best-characterized genetic region related to resistance/susceptibility to a wide range of infectious and immune-mediated diseases. Evidences suggest that MHC class II genes may play an important role in developing different types of tumors including breast cancer. Canine mammary gland tumors (CMTs) are the most common neoplasms in female dogs. In the current study, the association of canine MHC class II DLA-DRB1.2 genotypes with development of mammary gland tumor profiles in dogs was investigated. DLA-DRB1.2 allelic diversity was determined in 40 dogs (18 CMT cases and 22 controls) using HRM technique and DNA sequencing. Association of the DLA-DRB1.2 genotypes with CMT profiles was expressed as odds ratio (OR). Results Based on the histopathological typing of tumors, CMT cases were categorized into 4 groups: simple carcinoma, complex carcinoma, carcinoma arising in a benign tumor and special types of carcinoma. A total of eight HRM profiles (A to H) were identified in dogs sampled. The association study revealed a significant correlation between DLA-DRB1.2 genotypes with different CMT profiles. The E genotype was significantly associated with increased risk of carcinoma arising in a benign tumor, and the B genotype represented a positive correlation with complex carcinoma. Significant association was also observed between the heterozygosity of DLA-DRB1.2 genotypes and decreased risk of developing tumor in dogs. Conclusions These results provide additional support for the association between DLA-DRB1 genes and development of mammary gland tumors in dogs and could potentially be used for early diagnosis of neoplasia and identifying susceptible dogs.
Collapse
|
7
|
Zhou Q, Xu J, Zhao J, Zhang S, Pan W. Downregulation of CD99 and upregulation of human leukocyte antigen class II promote tumor aggravation and poor survival in patients with osteosarcomas. Onco Targets Ther 2014; 7:477-84. [PMID: 24711704 PMCID: PMC3969338 DOI: 10.2147/ott.s54765] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND CD99 is involved in the intracellular transport of human leukocyte antigen class II (HLA-II) protein. The aim of this study was to clarify the clinical value of CD99 and HLA-II expression in primary osteosarcoma. METHODS One hundred and thirty pairs of osteosarcoma and matched noncancerous bone tissues were evaluated by immunohistochemistry for CD99 and HLA-II expression. RESULTS Compared with the noncancerous bone tissues, the expression levels of CD99 (tumor versus normal: 2.96±0.09 versus 5.89±1.26, P<0.001) and HLA-II (tumor versus normal: 5.01±1.39 versus 1.92±0.06, P<0.001) proteins were respectively downregulated and upregulated in osteosarcoma tissues. CD99 and HLA-II were highly expressed in 49/130 (37.69%) and 107/130 (82.31%) of osteosarcoma tissues, respectively. In addition, the osteosarcoma patients with downregulation of CD99 and upregulation of HLA-II more frequently showed the presence of metastasis and recurrence and poor response to chemotherapy. Moreover, there was a negative correlation between CD99 and HLA-II expression in osteosarcoma tissues (r=-0.69, P=0.01). The patients with low CD99 expression correlated with poor prognosis of osteosarcoma, as opposed to HLA-II. Patients with CD99-low/HLA-II-high expression had the lowest overall and disease-free survival rates, and conjoined expression of CD99/HLA-II was an independent prognostic indicator of osteosarcoma. CONCLUSION These findings suggest for the first time that CD99 downregulation or HLA-II upregulation may be an important feature of human osteosarcoma. The combined detection of CD99/HLA-II coexpression may present a predictive and prognostic indicator in osteosarcoma.
Collapse
Affiliation(s)
- Quan Zhou
- Department of Orthopaedics, the second Hospital of Huai'an city Affiliated to Xuzhou Medical College and the second Hospital of Huai'an city, Huai'an, People's Republic of China
| | - Jin Xu
- Department of Orthopaedics, the second Hospital of Huai'an city Affiliated to Xuzhou Medical College and the second Hospital of Huai'an city, Huai'an, People's Republic of China
| | - Jiali Zhao
- Department of Orthopaedics, the second Hospital of Huai'an city Affiliated to Xuzhou Medical College and the second Hospital of Huai'an city, Huai'an, People's Republic of China
| | - Shaoxian Zhang
- Department of Orthopaedics, the second Hospital of Huai'an city Affiliated to Xuzhou Medical College and the second Hospital of Huai'an city, Huai'an, People's Republic of China
| | - Wei Pan
- Department of Orthopaedics, the second Hospital of Huai'an city Affiliated to Xuzhou Medical College and the second Hospital of Huai'an city, Huai'an, People's Republic of China
| |
Collapse
|
8
|
Atoum MF, Tanashat RQ, Mahmoud SAH. Negative Association of the HLA-DQB1*02 Allele with Breast Cancer Development among Jordanians. Asian Pac J Cancer Prev 2013; 14:7007-10. [DOI: 10.7314/apjcp.2013.14.11.7007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
9
|
Pan Q, Ning Y, Chen LZ, Zhang S, Liu ZZ, Yang XX, Wei W, Wei H, Li QG, Yue HN, Wang JX. Association of MHC class-III gene polymorphisms with ER-positive breast cancer in Chinese Han population. GENETICS AND MOLECULAR RESEARCH 2012; 11:4299-306. [PMID: 23079975 DOI: 10.4238/2012.september.17.1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Polymorphisms of the major histocompatibility complex (MHC) have been linked to many diseases, especially autoimmune disorders. Previous studies have shown that genetic variants in MHC class III are associated with breast cancer. To determine if there is an association between MHC class III and breast cancer risk in the Chinese Han population, we carried out a hospital-based case-control study in Guangdong and Jiangsu Provinces, including 216 histologically confirmed breast cancer patients and 216 healthy controls. Nine SNP markers distributed in the class III-coding region were detected using the Sequenom MassARRAY(®) iPLEX System. Deviation from Hardy-Weinberg equilibrium was observed for seven SNPs. There was no significant association between these seven SNP variants and breast cancer in these Chinese women (unconditional logistic regression analysis). However, chr6_31697494 at BAT2, one of the seven SNPs, was found to be significantly associated with both ER- and PR-positive breast cancer. In addition, both chr6_31911109 at C6orf48 and chr6_31975605 at ZBTB12, another two of the seven SNPs, show relevance with ER-positive breast cancer. In conclusion, this is the first evidence that genetic polymorphisms in the MHC class III region are significantly associated with ER-positive breast cancer in the Han Chinese population.
Collapse
Affiliation(s)
- Q Pan
- Laboratory of Medical Genetics, Huaian Maternal and Child Health Care Hospital, Huai'an, Jiangsu Province, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
HLA-DRB1,-DQA1 and -DQB1 Allele and Haplotype Frequencies in Female Patients with Early Onset Breast Cancer. Pathol Oncol Res 2011; 18:49-55. [PMID: 21720852 DOI: 10.1007/s12253-011-9415-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Accepted: 05/12/2011] [Indexed: 12/30/2022]
|
11
|
Xin YN, Lin ZH, Jiang XJ, Zhan SH, Dong QJ, Wang Q, Xuan SY. Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2011; 17:2248-2254. [PMID: 21633537 PMCID: PMC3092879 DOI: 10.3748/wjg.v17.i17.2248] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2010] [Revised: 12/09/2010] [Accepted: 12/16/2010] [Indexed: 02/06/2023] Open
Abstract
AIM To evaluate the association of human leukocyte antigen (HLA)-DQB1 alleles with hepatocellular carcinoma (HCC) through meta-analysis of published data. METHODS Case-control studies on HLA-DQB1 allele association with HCC published up to January 2010 were included in the analyses. The odds ratios (ORs) of HLA-DQB1 allele distributions in HCC patients were analyzed and compared with healthy controls. The meta-analysis software REVMAN 5.0 was applied for investigating heterogeneity among individual studies and for summarizing all the studies. A meta-analysis was performed using fixed-effect or random-effect methods, depending on the absence or presence of significant heterogeneity. Seven case-control studies containing 398 cases and 594 controls were included in the final analysis. RESULTS Among the five family alleles, two (DQB1*02 and DQB1*03) were found to be significantly associated with the risk of HCC. The combined OR for the association of DQB1*02 and DQB1*03 allele with the risk for HCC was 1.78 (95% CI: 1.05-3.03, P = 0.03) and 0.65 (95% CI: 0.48-0.89, P = 0.007), respectively. Among the 13 specific alleles, two (DQB1*0502 and DQB1*0602) were significantly associated with risk of HCC. The combined OR for the association of DQB1*0502 and DQB1*0602 allele with the risk for HCC was 1.82 (95% CI: 1.14-2.92, P = 0.01) and 0.58 (95% CI: 0.36-0.95, P = 0.03), respectively. No significant association was established for other HLA-DQB1 family alleles and specific alleles. CONCLUSION Our results support the hypothesis that specific HLA-DQB1 allele families and alleles might influence the susceptibility or resistance to HCC, although it needs further investigations.
Collapse
|
12
|
Gun FD, Ozturk OG, Polat A, Polat G. HLA class-II allele frequencies in Turkish breast cancer patients. Med Oncol 2011; 29:466-71. [DOI: 10.1007/s12032-011-9873-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2011] [Accepted: 02/17/2011] [Indexed: 10/18/2022]
|
13
|
Mahjoub S, Mehri S, Ghazouani E, Ouarda F, Boussada R, Zaroui A, Mechmeche R, Hammami M, Ben Arab S. HLA class II polymorphisms in Tunisian patients with dilated cardiomyopathy. ACTA ACUST UNITED AC 2010; 75:679-83. [PMID: 20136773 DOI: 10.1111/j.1399-0039.2009.01432.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Cardiomyopathies (CMs) are primary disorders of cardiac muscle. They are a major cause of morbidity and mortality for all ages and, like acquired forms of cardiovascular disease, often result in heart failure. Molecular genetic studies have made remarkable progress in defining the pathogenesis of CM. The present study was the first report to evaluate the relationship between class II major histocompatibility complex (MHC) genes (HLA-DRB1 and HLA-DQB1) and the genetic susceptibility to primary dilated cardiomyopathy (DCM) in Tunisian patients. The human leukocyte antigen (HLA)-DRB1 and -DQB1 alleles were analyzed in 76 patients with primary DCM and 111 ethnically matched healthy controls using polymerase chain reaction-sequence specific primers technique. An increased frequencies of HLA-DRB1*0401 (OR = 2.67, P < 0.001), HLA-DQB1*0302 (OR = 3.28, P = 0.001) and HLA-DQB1*0401 (OR = 6.26, P = 0.005) alleles were found in the patients with primary DCM compared with healthy controls. Individuals with HLA-DRB1*1301 (OR = 0.24, P < 0.001) and HLA-DQB1*0201 (OR = 0.49, P = 0.002) alleles have a protective effect against primary DCM. Two haplotypes were associated with increased risk of primary DCM: DRB1*0401/DQB1*0302 (OR = 4.53, P = 0.002) and DRB1*0401/DQB1*0401 (OR = 9.42, P = 0.004). In conclusion, our data suggest that the variation in class II HLA alleles could be a genetic factor involved in the susceptibility to primary DCM in the Tunisian population.
Collapse
Affiliation(s)
- S Mahjoub
- Unité d'Epidémiologie Génétique et Moléculaire, Faculté de Médecine de Tunis, Tunis, Tunisia
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Cantú de León D, Pérez-Montiel D, Villavicencio V, García Carranca A, Mohar Betancourt A, Acuña-Alonzo V, López-Tello A, Vargas-Alarcón G, Barquera R, Yu N, Yunis EJ, Granados J. High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study. BMC Cancer 2009; 9:48. [PMID: 19196481 PMCID: PMC2653544 DOI: 10.1186/1471-2407-9-48] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2008] [Accepted: 02/05/2009] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The development of breast cancer is multifactorial. Hormonal, environmental factors and genetic predisposition, among others, could interact in the presentation of breast carcinoma. Human leukocyte antigen (HLA) alleles play an important role in immunity (cellular immunity) and may be important genetic traits. HLAAllele-specific interaction has not been well established. Recently, several studies had been conducted in order to do so, but the results are controversial and in some instances contradictory. METHODS We designed a case-control study to quantify the association of HLA class I and II genes and breast cancer. HLA typing was performed by high resolution sequence-specific oligotyping after DNA amplification (PCR-SSOP) of 100 breast cancer Mexican mestizo patients and 99 matched healthy controls. RESULTS HLA-A frequencies that we were able to observe that there was no difference between both groups from the statistical viewpoint. HLA-B*1501 was found three times more common in the case group (OR, 3.714; p = 0.031). HLA-Cw is not a marker neither for risk, nor protection for the disease, because we did not find significant statistical differences between the two groups. DRB1*1301, which is expressed in seven cases and in only one control, observing an risk increase of up to seven times and DRB1*1602, which behaves similarly in being present solely in the cases (OR, 16.701; 95% CI, 0.947 - 294.670). DQ*0301-allele expression, which is much more common in the control group and could be protective for the presentation of the disease (OR, 0.078; 95% CI, 0.027-0.223, p = 0.00001). CONCLUSION Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation. The triggering factor seems to be restricted to certain ethnic groups and certain geographical regions since the relevant MHC alleles are highly diverse. This is the first study in Mexican population where high resolutions HLA typing has been performed in order to try to establish an association with malignancy.
Collapse
Affiliation(s)
- David Cantú de León
- Department of Gynecologic Oncology, Instituto Nacional de Cancerología de México, Mexico City, Mexico.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Sirugo G, Hennig BJ, Adeyemo AA, Matimba A, Newport MJ, Ibrahim ME, Ryckman KK, Tacconelli A, Mariani-Costantini R, Novelli G, Soodyall H, Rotimi CN, Ramesar RS, Tishkoff SA, Williams SM. Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet 2008; 123:557-98. [PMID: 18512079 DOI: 10.1007/s00439-008-0511-y] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2008] [Accepted: 05/07/2008] [Indexed: 01/13/2023]
Abstract
Africa is the ultimate source of modern humans and as such harbors more genetic variation than any other continent. For this reason, studies of the patterns of genetic variation in African populations are crucial to understanding how genes affect phenotypic variation, including disease predisposition. In addition, the patterns of extant genetic variation in Africa are important for understanding how genetic variation affects infectious diseases that are a major problem in Africa, such as malaria, tuberculosis, schistosomiasis, and HIV/AIDS. Therefore, elucidating the role that genetic susceptibility to infectious diseases plays is critical to improving the health of people in Africa. It is also of note that recent and ongoing social and cultural changes in sub-Saharan Africa have increased the prevalence of non-communicable diseases that will also require genetic analyses to improve disease prevention and treatment. In this review we give special attention to many of the past and ongoing studies, emphasizing those in Sub-Saharan Africans that address the role of genetic variation in human disease.
Collapse
Affiliation(s)
- Giorgio Sirugo
- Medical Research Council Laboratories, Fajara, The Gambia, West Africa.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
|
17
|
Chen PC, Tsai EM, Er TK, Chang SJ, Chen BH. HLA-DQA1 and -DQB1 allele typing in southern Taiwanese women with breast cancer. Clin Chem Lab Med 2007; 45:611-4. [PMID: 17484621 DOI: 10.1515/cclm.2007.132] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The pathogenesis of breast cancer is multifactorial. Genetic predisposition, environmental factors, hormones and even infection agents are thought to interact in the manifestation of breast cancer. In particular, human leukocyte antigen (HLA) alleles play a pivotal role in cellular immunity and may be an important genetically determined host trait. Regardless of the importance and functions of HLA genes in the evolution of cancer, the allele-specific association of HLA molecules in cancer patients has not been well established. Recently, a few studies have concentrated on the association between HLA and breast cancer, but the results of these studies are controversial. METHODS We designed a study to evaluate the association between the genotype of HLA class II genes and breast cancer. HLA-DQA1 and -DQB1 polymorphisms were determined by PCR with sequence-specific primers (PCR-SSP) in 101 Taiwanese women patients with breast cancer and 115 matched control subjects. RESULTS Using PCR-SSP typing, HLA-DQA1 and -DQB1 locus comparison of allele frequencies between breast cancer patients and healthy controls showed no significant difference. CONCLUSIONS We have established a significant lack of HLA-DQA1 and -DQB1 association with breast cancer in southern Taiwanese women. The results of this study may provide information for further clarification of the etiology of breast cancer in this region.
Collapse
Affiliation(s)
- Po-Chih Chen
- Department of Laboratory Medicine, Kaohsiung Medical University Chung-Ho, Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | | | | | | | | |
Collapse
|